Protara Therapeutics (TARA) Income from Continuing Operations (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Income from Continuing Operations of 28925000.0 for Q1 2026, down 58.4% year-over-year from 69527369.36 in Q1 2025, and down 48.42% quarter-over-quarter from 19489000.0 in Q4 2025.
Protara Therapeutics (TARA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Income from Continuing Operations for 14 consecutive years, with 28925000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 58.4% year-over-year to 28925000.0; the TTM figure through Mar 2026 stood at 88760000.0 (down 52.32% YoY), while the FY2025 annual figure was 148061000.0, down 25.13% from the prior year.
- Income from Continuing Operations eased to 28925000.0 in Q1 2026 per TARA's latest filing, from 19489000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9132000.0 in Q3 2022 and bottomed at 40059000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 16516176.47 across 5 years, with a median of 13437000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 225.29% — and 2023, when it soared 67.56%.
- Protara Therapeutics' Income from Continuing Operations stood at 40059000.0 in 2022, then jumped by 67.56% to 12996000.0 in 2023, then increased by 12.45% to 11378000.0 in 2024, then tumbled by 71.29% to 19489000.0 in 2025, then slumped by 48.42% to 28925000.0 in 2026.
- Business Quant data shows TARA's Income from Continuing Operations at 28925000.0 in Q1 2026, 19489000.0 in Q4 2025, and 19370000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | -24.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.66 Mn |
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -19.49 Mn |
| Sep 30, 2025 | -19.37 Mn |
| Jun 30, 2025 | -20.98 Mn |
| Mar 31, 2025 | -18.26 Mn |
| Dec 31, 2024 | -11.38 Mn |
| Sep 30, 2024 | -17.69 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Mar 31, 2024 | -15.46 Mn |
| Dec 31, 2023 | -13.00 Mn |
| Sep 30, 2023 | -11.39 Mn |
| Jun 30, 2023 | -13.44 Mn |
| Mar 31, 2023 | -9.46 Mn |
| Dec 31, 2022 | -40.06 Mn |
| Sep 30, 2022 | -9.13 Mn |
| Jun 30, 2022 | -10.21 Mn |
| Mar 31, 2022 | -11.61 Mn |
| Dec 31, 2021 | -12.32 Mn |
| Sep 30, 2021 | -10.83 Mn |